← Back to Search

Radiation Therapy

Image-Guided Radiation + Immunotherapy for Lung Cancer

N/A
Waitlist Available
Led By Michael Gensheimer
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
ECOG performance status 0-2
Has at least one extracranial tumor safely treatable with radical-dose radiation therapy and that has not been previously treated with radiation
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 years
Awards & highlights

Study Summary

This trial studies radiation therapy as a treatment for non-small cell lung cancer.

Who is the study for?
This trial is for adults over 18 with stage IV non-small cell lung cancer or those whose earlier-stage lung cancer has spread. They must have been on standard immunotherapy for at least four weeks, be stable in terms of symptoms and performance status, and show a certain response to treatment on recent scans. Pregnant women or those not using contraception are excluded.Check my eligibility
What is being tested?
The study is testing high-dose image guided radiation therapy in patients with metastatic non-small cell lung cancer who are also undergoing immunotherapy. The goal is to see if this combination improves the body's response to the immunotherapy treatment.See study design
What are the potential side effects?
While specific side effects aren't listed here, radiation therapy can generally cause fatigue, skin reactions at the treatment site, and may affect normal tissue function where it's applied. Immunotherapies can lead to immune-related inflammation in various organs.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can take care of myself and perform daily activities.
Select...
I have a tumor outside the brain that can be treated with high-dose radiation and hasn't been treated with radiation before.
Select...
I am 18 years old or older.
Select...
My lung cancer is at stage IV or was initially at an earlier stage but has now spread.
Select...
I will be on immunotherapy for at least 3 more months.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression-free survival
Secondary outcome measures
Change in circulating tumor deoxyribonucleic acid levels as measured using CAncer Personalized Profiling by deep Sequencing
Change in immune marker levels as measured from peripheral blood using flow cytometry performed by the Human Immune Monitoring Core at Stanford University
Incidence of acute (0-6 months) and late (> 6 months) grade 3-5 toxicity
+1 more
Other outcome measures
Patterns of response and progression
Progression free survival
Time to discontinuation of study immunotherapy agent

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Immunotherapy plus Image-guided Radiation TherapyExperimental Treatment2 Interventions
Patients undergo radical-dose image guided radiation therapy daily for up to 10 days (within 2 weeks) while continuing their prior treatment with the treating physician's choice of regular medical care immunotherapy.
Group II: Immunotherapy Alone (Regular Medical Care)Active Control1 Intervention
Patients who decline to undergo radiation therapy will continue their prior treatment with the treating physician's choice of regular medical care immunotherapy.

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,386 Previous Clinical Trials
17,333,964 Total Patients Enrolled
Michael GensheimerPrincipal InvestigatorStanford University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any opportunities to enroll in this experiment currently?

"The clinicaltrials.gov website indicates that this trial, initially posted on the 28th of June 2017 and last modified on September 1st 2022 has already ceased its recruitment activities. Nevertheless, there are still 1921 other studies currently seeking participants."

Answered by AI
~6 spots leftby Apr 2025